Literature DB >> 2167716

The effect of age on the pharmacokinetics of ifosfamide.

M J Lind1, J M Margison, T Cerny, N Thatcher, P M Wilkinson.   

Abstract

The effect of age on the pharmacokinetics of ifosfamide was studied in 20 patients with advanced non small cell lung cancer. A positive correlation was found between the elimination half-life of ifosfamide and age (r = 0.48, 0.05 less than P less than 0.01). This was due to an increase in volume of distribution with age (r = 0.66, 0.001 less than P less than 0.01). Total plasma clearance, renal clearance and non renal clearance did not change with age. Age did not affect the autoinduction of ifosfamide metabolism. Further studies are needed to demonstrate any adverse effects of ifosfamide in the elderly.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2167716      PMCID： PMC1368286          DOI： 10.1111/j.1365-2125.1990.tb03754.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  15 in total

1.  Anatomy of body water and electrolytes.

Authors:  I S EDELMAN; J LEIBMAN
Journal:  Am J Med       Date:  1959-08       Impact factor: 4.965

2.  The oxazaphosphorines.

Authors:  N Brock
Journal:  Cancer Treat Rev       Date:  1983-09       Impact factor: 12.111

3.  [Ifosfamide in comparison with cyclophosphamide in advanced ovarian carcinomas (author's transl)].

Authors:  G Teufel; A Pfleiderer
Journal:  Geburtshilfe Frauenheilkd       Date:  1976-03       Impact factor: 2.915

4.  The effects of age and liver disease on the disposition and elimination of diazepam in adult man.

Authors:  U Klotz; G R Avant; A Hoyumpa; S Schenker; G R Wilkinson
Journal:  J Clin Invest       Date:  1975-02       Impact factor: 14.808

5.  Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557).

Authors:  H O Klein; P D Wickramanayake; E Christian; C Coerper
Journal:  Cancer       Date:  1984-09-15       Impact factor: 6.860

Review 6.  Pharmacokinetics in the elderly.

Authors:  J Crooks; K O'Malley; I H Stevenson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

7.  A simple quantitative HPLC assay for ifosfamide in biological fluids.

Authors:  J M Margison; P M Wilkinson; T Cerny; N Thatcher
Journal:  Biomed Chromatogr       Date:  1986-06       Impact factor: 1.902

8.  Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.

Authors:  B M Bryant; M Jarman; H T Ford; I E Smith
Journal:  Lancet       Date:  1980-09-27       Impact factor: 79.321

9.  Evaluation of cis-diamminedichloroplatinum(II) combined with metoclopramide or sodium thiosulfate on L1210 leukemia in vitro and in vivo.

Authors:  J J Catino; D M Francher; J E Schurig
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.

Authors:  N E Sladek; D Doeden; J F Powers; W Krivit
Journal:  Cancer Treat Rep       Date:  1984-10
View more
  11 in total

1.  All half-lives are wrong, but some half-lives are useful.

Authors:  J G Wright; A V Boddy
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  Pharmacology of anticancer drugs in the elderly population.

Authors:  Hans Wildiers; Martin S Highley; Ernst A de Bruijn; Allan T van Oosterom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  The aging kidney: a review--part II.

Authors:  Fred G Silva
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 4.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 6.  The influence of age and sex on the clearance of cytochrome P450 3A substrates.

Authors:  Monette M Cotreau; Lisa L von Moltke; David J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma.

Authors:  S A Corlett; D Parker; H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

Review 8.  Dosing and side-effects of ifosfamide plus mesna.

Authors:  W P Brade; K Herdrich; U Kachel-Fischer; C E Araujo
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 9.  Ifosfamide pharmacokinetics.

Authors:  L D Lewis
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

10.  Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients.

Authors:  C P Granvil; J Ducharme; B Leyland-Jones; M Trudeau; I W Wainer
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.